Monte Rosa Therapeutics, Inc. GLUE Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monte Rosa Therapeutics, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s additional paid-in capital?
- Monte Rosa Therapeutics, Inc. (GLUE) reported additional paid-in capital of $1.05B in Q1 2026.
- How has Monte Rosa Therapeutics, Inc.'s additional paid-in capital changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s additional paid-in capital increased by 56.4% year-over-year, from $670.19M to $1.05B.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s additional paid-in capital?
- Over 5 years (2020 to 2025), Monte Rosa Therapeutics, Inc.'s additional paid-in capital has grown at a 346.1% compound annual growth rate (CAGR), from $404K to $714.09M.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.